Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lithium augmentation therapy in refractory depression-update 2002.

Michael Bauer1, Anna Forsthoff, Christopher Baethge

  • 1Klinik fur Psychiatrie und Psychotherapie, Charite Campus Mitte Humboldt-Universitat zu Berlin, Schumannstr. 20-21, 10117, Berlin, Germany, michael.bauer@charite.de

European Archives of Psychiatry and Clinical Neuroscience
|August 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital crisis counseling during wartime: Pre-post outcomes and user experience in Ukrainian and German samples.

Internet interventions·2026
Same author

Frequency and Correlates of Inaccurate Psychiatric Diagnoses in 401 Adults Hospitalized for Major Depressive Disorder: A Comparison of Clinical vs. Research Interview-Based Diagnoses.

CNS spectrums·2026
Same author

Psychomotor slowing as a predictor of treatment outcomes in major depressive disorder with acute suicidality: Insights from the OASIS-D study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry.

The lancet. Psychiatry·2026
Same author

The Global Cost of Silencing Science.

La Tunisie medicale·2026
Same author

Climate-Related and Nature-Based Interventions for Mental Health: An Umbrella Review and Meta-Analysis.

JAMA psychiatry·2026
Same journal

Abnormal emotional intensity processing in individuals at clinical high risk for psychosis: evidence from event-related potentials.

European archives of psychiatry and clinical neuroscience·2026
Same journal

The role of attention in perceptual biases in patients with schizophrenia spectrum disorder and healthy controls.

European archives of psychiatry and clinical neuroscience·2026
Same journal

Effects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis?

European archives of psychiatry and clinical neuroscience·2026
Same journal

Effects of xanomeline-trospium on the gut-lung microbiota axis and susceptibility to LPS-induced acute lung injury in male and female mice.

European archives of psychiatry and clinical neuroscience·2026
Same journal

Association of the red blood cell distribution width-to-albumin ratio with incident depression and depressive symptom trajectories in older adults.

European archives of psychiatry and clinical neuroscience·2026
Same journal

Major depressive disorder-alcohol use disorder comorbidity: diagnosis, mechanisms and treatment.

European archives of psychiatry and clinical neuroscience·2026
See all related articles

Lithium augmentation significantly improves treatment outcomes for patients with major depression who do not respond to standard antidepressants. This well-documented strategy offers a first-line option for refractory depression.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Lithium has a long history of use in augmenting antidepressant efficacy.
  • Treatment-resistant depression (TRD) poses a significant clinical challenge.
  • Evidence for lithium's role in TRD requires systematic evaluation.

Purpose of the Study:

  • To review existing evidence on the clinical efficacy of lithium augmentation in refractory depression.
  • To assess the effectiveness of lithium in patients unresponsive to conventional antidepressants.
  • To determine if lithium augmentation is a viable first-line strategy for TRD.

Main Methods:

  • Systematic literature search of Medline and reference lists (1980-2002).
  • Inclusion of prospective studies: open-label, double-blind, placebo-controlled, or comparator trials.

Related Experiment Videos

  • Analysis of 27 studies involving 803 patients with treatment-resistant depression.

    • Main Results:

    • Majority of randomized controlled trials showed substantial efficacy of lithium augmentation.
    • In placebo-controlled trials, lithium response rate was 45% versus 18% for placebo (p<0.001).
    • Approximately 50% of patients responded to lithium augmentation within 4 weeks across all studies.

    Conclusions:

    • Lithium is the most well-documented augmentation strategy for refractory depression.
    • Lithium augmentation demonstrates significant clinical efficacy in non-responders.
    • Consider lithium as a first-line treatment for major depression unresponsive to standard antidepressants.